Company intelligence / Profile preview
Mononuclear Therapeutics Limited
Shatin, New Territories, Hong Kong SAR Chinamonotx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Mononuclear Therapeutics is developing umbilical cord blood mononuclear cell therapies for neurological conditions such as spinal cord injury, stroke, and age-related macular degeneration. Their programs are in preclinical stages, with collaborations for animal studies and a focus on building internationally accredited cell banks[1][2][4].
- Therapeutic areas
- OphthalmologyNeurology
- Modalities
- Cell therapy (umbilical cord blood mononuclear cells)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Hong Kong Science and Technology Parks Corporation (HKSTP)[3]Chinese University of Hong Kong[3]
Beyond the preview
Go deeper on Mononuclear Therapeutics Limited.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mononuclear Therapeutics Limited.